Diabetic nephropathy (DN) is the leading cause of end stage renal disease worldwide [1]. Chronic hyperglycemia causes progressive kidney damage in diabetic patients, which is characterized by three main findings: (1) persistent albuminuria (more than 300 mg/day or more than 200 μg/min), (2) progressive and irreversible decline in glomerular filtration rate (GFR), and (3) increased arterial blood pressure [2]. In most DN cases, pathological changes are prominent in the glomeruli as well as the renal tubules of diabetes patients’ kidneys even before the onset of microalbuminuria. In the glomeruli, the early adaptive changes are marked by glomerular hypertrophy and thickening of the glomerular basement membrane (GBM). As the disease progresses, the mesangial matrix expands, and the mesangial cells increase in size, leading to glomerulosclerosis and the development of nodular lesions also known as Kimmelstiel-Wilson nodules, a hallmark of DN. Similarly, the tubules also undergo early hypertrophy and thickening of the tubular basement membrane (TBM), which then progress to tubulointerstitial fibrosis and inflammation at later stages of the disease [3].

Growing body of evidences has shown that DN is induced by multiple factors such as impaired glucose signaling, increased blood pressure, imbalance in the cellular redox status, inflammation and altered protein folding, and turnover within the renal cells. Additionally, several signaling pathways are implicated in the development and progression of DN [4]. Akt, a 57 KDa serine/threonine kinase that regulates numerous cellular functions such as transcription, translation, cell proliferation, and survival, is thought to play a critical role in induced complications [5]. It has been shown that Akt increases the production of extracellular matrix (ECM) proteins such as collagen-I, collagen-IV, and laminin in diabetic kidney [6, 7]. In addition, the activation of PI3K/Akt pathway in renal tubules has been shown to cause tubular hypertrophy via two mechanisms: (1) by a cell cycle-dependent mechanism and (2) by altering protein translation through phosphorylation of the protein translation regulator 4E-BP1 [8–10].
The extracellular signal-regulated kinase (ERK) pathway is another crucial signaling network involved in numerous cellular processes [11]. Under hyperglycemia, the Ras-Raf-MEK-ERK signal transduction cascade becomes activated and leads to the activation of renin-angiotensin-aldosterone-system (RAAS), which is well known to cause renal injury [4, 12]. Moreover, ERK has been shown to induce vascular endothelial growth factor (VEGF) and transforming growth factor-beta 1 (TGF-β1), which causes albuminuria, increase in GFR, and kidney fibrosis [4, 10, 13]. Furthermore, several studies have showed crosstalk between ERK pathway and other pathways in DN such as advanced glycation end products (AGE) and protein kinase C (PKC) pathways [14]. Therefore, ERK activation is considered one of the significant signaling events in DN.

Aldose reductase (AR; EC 1.1.1.21) is a member of aldoketo reductase (AKR) superfamily [15], which constitutes more than 100 structurally related proteins [16]. AR is the rate-limiting enzyme in the polyol pathway, which is responsible for the reduction of glucose to sorbitol using NADPH as a cofactor. Subsequently, sorbitol is converted to fructose by sorbitol dehydrogenase using NAD + as a cofactor. In normoglycemic conditions, glucose serves as a poor substrate for AR due to the high Km values of AR for glucose. Under hyperglycemic conditions, there is increase in flux of glucose through polyol pathway, which leads to imbalances in cofactors and products causing several deleterious effects such as osmotic stress, oxidative stress, increased AGE, and activation of PKC pathway [17].

Many studies have investigated the role of polyol pathway in the development of DN and evaluated the protective role of various aldose reductase inhibitors (ARIs) [18–24]. ARIs are thought to exert their beneficial effects by decreasing hyperfiltration, albuminuria, and accumulation of ECM proteins (antifibrotic effects) without affecting the blood glucose or HbA1c levels [25]. In addition, plethora of in vitro data supports the link between polyol pathway and PKC activity and TGF-β1 and ECM protein production, which suggest the involvement of this pathway in fibrotic changes observed in DN [26–29]. Although several preclinical studies using ARIs have demonstrated nephroprotective effects against DN, the results from most clinical trials are not very encouraging [25]. There are several challenges to be faced when targeting AR enzyme including the difficulty of developing ARIs with high specificity towards ALR2 isoform and the use of optimum doses for AR inhibition. Moreover, the efficacy of ARIs depends on the levels of expression of AR in target tissues and the degree of involvement of polyol pathway in the development of diabetic complications, which varies significantly across diabetic patients [25, 30].

In this study, we have investigated the effects of high glucose concentrations on rat renal proximal tubular cells cultured in vitro. The study is aimed to investigate the key molecular pathways that are activated in renal cells under high glucose conditions and to identify the cellular markers that mediate hyperglycemia-induced renal cell injury. We hypothesized that exposing renal tubular cells to high glucose concentrations would induce AR expression and, thus, inhibiting AR using epalrestat (a potent ARI) would confer protection against high glucose-induced renal cell injury.

2. Materials and Methods

2.1. Cell Culture. Normal rat kidney cells (NRK-52E; Health Protection Agency, UK) were cultured in Dulbecco’s modified Eagle medium (DMEM, Life Technologies, UK) supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine, and 1% penicillin/streptomycin. The cells were maintained at 37°C in 5% CO_2 incubator. To obtain an in vitro model that represents the features of DN, cells were divided into 3 groups: (1) control, where cells were treated with DMEM medium containing 5 mM glucose and 1% FBS, (2) high glucose treated, where cells were treated with DMEM medium containing 30 mM glucose and 1% FBS, and (3) osmotic control, where cells were treated with DMEM medium containing 5 mM glucose and 25 mM mannitol with 1% FBS to simulate a milieu that is osmotically equivalent to the 30 mM high glucose media. The cells were exposed to the above-mentioned conditions for 24, 48, and 72 hours. To investigate the effects of AR inhibition on high glucose-induced stress in renal cells, NRK-52E cells were cotreated with epalrestat (Sigma Aldrich, Germany) at 1 μM concentration and compared against vehicle-treated controls.

2.2. Assessment of Cell Viability. NRK-52E cells were seeded on 96-well plates and treated according to the aforementioned protocol. At the end point, media were removed and replaced by 100 μl of fresh serum-free media and 10 μl of 5 mg/ml MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) reagent (Sigma Aldrich, Germany). The plates were incubated at 37°C for 3-4 hours. The purple formazan crystals formed were solubilized in 50 μl of dimethylsulfoxide (DMSO), and the absorbance was measured at 570 nm using a microplate reader. Absorbance value from the control group was set as 100% and the values from treatment groups were expressed as percentage of control.

2.3. Western Blotting. NRK-52E cells were seeded on 6-well plates. At the end point, cells were scrapped and lysed in 60 mM Tris, pH 6.8 buffer containing 2% SDS. Samples were sonicated for 10–15 seconds and centrifuged at 16,000 × g for 15 minutes at 4°C prior to determination of protein concentrations using bichinchoninic acid (BCA) protein assay (Pierce, USA). About 20 to 40 μg of protein from each group was loaded onto 10% or 12% sodium dodecyl sulfate-polyacrylamide gels (SDS-PAGE) and resolved by electrophoresis and transferred onto polyvinylidene fluoride (PVDF) membranes. The membranes were blocked with 5% nonfat milk for 1 hour and then probed with specific primary antibodies (overnight at 4°C) for the following: aldose reductase (ab131182 Abcam, 1:1000, mouse), p-Akt (ab81283 Abcam, 1:2000, rabbit), Akt (ab32205 Abcam, 1:2000, rabbit), p-ERK (9106 cell signaling, 1:1000, mouse), and ERK (9102 cell signaling, 1:1000, rabbit). Subsequently, membranes were incubated with horseradish peroxidase-(HRP-) conjugated goat anti-mouse IgG (1:10,000; Abcam,
UK) or goat anti-rabbit IgG (1:20,000; Abcam, UK) secondary antibodies for 1 hour at room temperature. The immunoreactivity was visualized with Optiblot ECL detection kit (Abcam, UK) using Syngene (G-BOX Chemi XX6) imaging system and analyzed using Scion Image software. The densitometry values were normalized to actin (used as loading control) and expressed as percentage of control.

2.4. Assessment of Mitochondrial Membrane Potential (JC-1 Assay). The high glucose-induced alterations in the mitochondrial membrane potential in NRK-52E cells were assessed using JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetracyanobenzimidazolylcarbocyanine iodide; T-3168, Life Technologies, UK) as described previously [31]. Briefly, after 24 or 48 h high glucose treatment, cells were stained with JC-1 reagent (10 μM) for 30 minutes at 37 °C in dark, and the fluorescence was measured using a microplate reader (SpectraMax, USA) at excitation/emission (Ex/Em) 488 nm/529 nm to measure monomers and Ex/Em 488 nm/590 nm to measure J-aggregates. The ratio of fluorescent intensity of J-aggregates (red) to that of monomers (green) was calculated to determine changes in mitochondrial membrane potential. For fluorescence microscopy, cells were stained with JC-1 as described above and imaged under fluorescent microscope (Olympus, USA) with TRITC filter at 200x magnification.

2.5. Cell Cycle Analysis. Following 24 or 48 h high glucose treatment, NRK-52E cells were fixed in 70% ethanol and kept at −20 °C. On the day of analysis, cells were pelleted out by centrifugation at 1000×g for 5 minutes at 4 °C and stained with Tali® cell cycle solution (Life Technologies, UK) in dark for 30 minutes to achieve a cell density of 1 × 10^5–5 × 10^5 cells/ml for analysis using Tali image-based cytometer (Life Technologies, UK).

2.6. Statistical Analysis. All values were calculated as a percentage of control (5 mM glucose-treated group) and expressed as Mean ± SEM. One-way ANOVA test followed by Tukey's post hoc test was performed using GraphPad Prism 6 to detect statistical differences between groups. P < 0.05 was considered statistically significant.

3. Results

3.1. Effect of High Glucose on the Viability and Relative Mitochondrial Membrane Potential of Renal Proximal Tubular Cells. NRK-52E cells were exposed to high glucose media (30 mM) for 24, 48, and 72 hours. 30 mM mannitol was used as osmotic control. At the endpoint, cell viability was assessed by MTT assay. It was observed that when using cells at low passage number (P2 to P6), there was a significant decrease in viability after 48 hours to 84%, which further declined to 68% after 72 h (Figure 1(a)). Intriguingly, the high glucose-induced decrease in viability after 48 and 72 h exposure was not reproducible when using cells with passage numbers higher than P7 (data not shown). Thus, we chose to perform all experiments on NRK-52E cells between passage numbers P2 to P6.

Alterations in the relative mitochondrial membrane potential (Δψm) of NRK-52E cells following exposure to high glucose concentrations were assessed using JC-1 staining. JC-1 is a cationic dye, which at high Δψm forms J-aggregate with red fluorescence, while at low Δψm it remains as monomers with green fluorescence. Therefore, the ratio of red to green
fluorescence is indicative of the polarization status of the mitochondria membrane. NRK-52E cells exposed to 30 mM glucose for 24 h and stained with JC-1 showed increased green fluorescence, and the red to green fluorescence ratio was 81% as compared to control. Although the mitochondrial depolarization was sustained after 48 h of high glucose exposure, it was not statistically significant (Figure 1(b)). These findings indicate that acute high glucose exposure induces transient mitochondrial depolarization in renal tubular cells.

3.2. Effect of High Glucose on Akt and ERK Signaling Pathways in Renal Tubular Cells. Activation of Akt and ERK signaling pathways was investigated in renal tubular cells following exposure to high glucose for 10 minutes, 30 minutes, 1 hour, 2 hours, and 4 hours. As shown in Figures 2 and 3, there was an acute and transient induction of p-Akt and p-ERK after 10 minutes of high glucose exposure, which then subsided at further time points tested.

3.3. Effect of High Glucose on Aldose Reductase (AR) Expression in Renal Tubular Cells. To investigate if aldose reductase (AR) was induced in the model, AR expression was measured in NRK-52E cells subjected to high glucose treatment. Although the AR expression remained unchanged after 24 hours of high glucose treatment, it was significantly induced at 48 hours by about 1.5-fold as compared to control (Figure 4). A small induction in AR protein expression was also observed in cells exposed to high osmolar media (30 mM mannitol) at 48 hours.

3.4. Effect of Epalrestat on High Glucose-Induced Alterations in Renal Cell Viability and Cell Cycle. To examine the protective effect of aldose reductase (AR) inhibition on high glucose-induced renal cell injury, NRK-52E cells were exposed to high glucose in presence of 1 μM epalrestat (an AR inhibitor) for 48 hours. At the endpoint, cell viability was measured using MTT assay. As observed earlier, with 48 hours’ high glucose treatment, the cell viability declined to 84% (P < 0.05) to that of control. In contrast, coinubcation of cells with epalrestat at 1 μM was able to attenuate high glucose induced cell death (Figure 5(a)). In addition, when cells were exposed to high glucose medium for 48 h in presence of epalrestat, the percentage of cells increased in the G1 phase when compared to control but was not statistically significant (Figure 5(b)).

3.5. Effect of Epalrestat on Mitochondrial Membrane Potential Depolarization in Renal Tubular Cells. The effect of epalrestat on the mitochondrial membrane potential in renal tubular cells was assessed after 24 hours of high glucose exposure using JC-1 staining. Coincubation of cells with 1 μM epalrestat
reversed the depolarization observed with 24 hours’ high glucose treatment. Fluorescent cell images further confirmed this finding, that is, an intense green staining observed in high glucose-treated cells, whereas the cells coincubated with epalrestat show a mixed red and green staining pattern similar to control cells (Figure 6).

3.6. Effect of Epalrestat on High Glucose-Induced Activation of Akt and ERK Pathways in Renal Tubular Cells. NRK-52E cells were exposed to 10 minutes of high glucose in presence of epalrestat to investigate the effect of aldose reductase inhibition on high glucose-induced activation of Akt and ERK pathways. As seen in Figure 7, epalrestat cotreatment attenuated high glucose-mediated induction of Akt and ERK pathways, which suggests crosstalk between these two pathways and the polyol pathway in renal cells under high glucose conditions.

4. Discussion

Our studies indicate that exposure of NRK-52E cells to 30 mM glucose causes a progressive decline in cell viability, that is, 84% viability after 48 hours and 68% viability after 72 hours as compared to control (100%). Similarly, a study by Park et al. using primary rabbit renal proximal tubular cells observed inhibition of cell proliferation over 24, 48, and 72 hours following exposure to 25 mM glucose [32]. It has been shown that high glucose induces mitochondrial alterations and dysfunction, which ultimately leads to apoptosis. In the current study, the effect of high glucose on mitochondrial membrane potential was tested in NRK-52E cells using JC-1 dye. After 24 hours, there was a slight decrease (81% compared to control) in mitochondrial membrane potential, which was sustained at 48h (86% compared to control) indicating that high glucose treatment induces mitochondrial depolarization in renal tubular cells. Our finding is in line with other studies, which demonstrated the onset of mitochondrial dysfunction in human kidney cells (HK-2) following exposure to high glucose medium [33–35]. Therefore, these findings suggest that tubular cell death observed in the current model might be initiated by alterations in mitochondrial function.

PI3K/Akt pathway is a vital pathway that is implicated in numerous cellular processes [36]. Several studies have revealed impairments in the PI3K/Akt pathway during diabetes and signified its role in the development of diabetic complications [8, 37, 38]. For example, hyperglycemia has been shown to induce collagen-I synthesis in mesangial cells by stimulating cytokines such as TGF-β and epidermal...
**Figure 4:** Effect of high glucose (30 mM) on aldose reductase (AR) expression in NRK-52E cells after 24 and 48 h as measured by western blotting. (a) A representative western blot showing the expression of AR in comparison to the loading control β-actin. (b) Bar graph with densitometric analysis of AR expression (normalized to β-actin). Values were expressed as percentage Mean ± SEM (n = 3) relative to control. *P < 0.05 compared to control.

**Figure 5:** Effects of epalrestat on high glucose-induced renal cell injury and cell cycle progression. (a) Cell viability of NRK-52E cells after exposure to high glucose with and without 1 μM epalrestat for 48 h as determined by MTT assay. Values were expressed as percentage Mean ± SEM (n = 3) relative to vehicle-treated control. *P < 0.05 compared to control. (b) Distribution of NRK-52E cells along cell cycle after incubation with high glucose and mannitol in the presence or absence of epalrestat (1 μM). Summarized data were reported in Table 1.
Table 1: Cell cycle analysis (using Tali image-based cytometer) of NRK-52E cells exposed to 30 mM glucose or osmotic control media with or without epalrestat (1 μM) for 48 h.

| Treatment groups | G1       | S        | G2        |
|------------------|----------|----------|-----------|
| Vehicle-treated control | 51.5 ± 1.2 | 27.75 ± 5.5 | 19.25 ± 3.5 |
| Vehicle-treated high glucose | 59 ± 2    | 27.33 ± 4.7 | 13 ± 5.6  |
| Vehicle-treated osmotic control | 71.5 ± 4.5 | 23 ± 5   | 4 ± 0.1   |
| Control + 1 μM epalrestat | 49.7 ± 3.7  | 26 ± 5.9  | 21.25 ± 5.9 |
| High glucose + 1 μM epalrestat | 61.5 ± 3.9  | 23.5 ± 5.2 | 14.5 ± 3.1 |
| Osmotic control + 1 μM epalrestat | 62.67 ± 4.3 | 22.33 ± 6.3 | 15.67 ± 3.9 |

![Figure 6: Assessment of relative mitochondrial membrane potential in NRK-52E cells by JC-1 staining. (a) Bar graph showing fluorescence values after 24 h of high glucose exposure with and without 1 μM epalrestat using JC-1 staining. Values were expressed as percentage Mean ± SEM of J-aggregate (excitation/emission 488/529) to monomer (excitation/emission 488/590) ratio compared to control. * P < 0.05 compared to control. (b) Representative JC-1 stained images of NRK-52E cells treated with high glucose and osmotic control media in the presence or absence of 1 μM epalrestat visualized under 400x magnification using fluorescence microscope.](image-url)

![Figure 6: Assessment of relative mitochondrial membrane potential in NRK-52E cells by JC-1 staining. (a) Bar graph showing fluorescence values after 24 h of high glucose exposure with and without 1 μM epalrestat using JC-1 staining. Values were expressed as percentage Mean ± SEM of J-aggregate (excitation/emission 488/529) to monomer (excitation/emission 488/590) ratio compared to control. * P < 0.05 compared to control. (b) Representative JC-1 stained images of NRK-52E cells treated with high glucose and osmotic control media in the presence or absence of 1 μM epalrestat visualized under 400x magnification using fluorescence microscope.](image-url)
Figure 7: NRK-52E cells were exposed to high glucose (HG) with and without epalrestat (EPS) for 10 minutes and assessed for its effect on Akt and ERK pathways. Left panel showing representative blots for Akt and ERK1 and ERK2, and the right panel showing densitometric analysis of the bands. Values were expressed as Mean ± SEM (n = 3). *P < 0.05 compared to control; **P < 0.05 compared to HG-treated group.

Glucose to mimic advanced stages of DN [47]. Serum (FBS) concentration is another crucial factor in the development of an in vitro DN model. In our model, serum deprivation has greatly affected the growth and morphology of NRK-52E cells, and consistent results were obtained when cells were exposed to 30 mM glucose media containing 1% FBS for 24 and 48 hours.

It has been shown that activation of polyol pathway due to hyperglycemia in renal cells plays a pivotal role in the development of DN [48]. Therefore, it is hypothesized that inhibiting aldose reductase enzyme, the rate-limiting enzyme in the polyol pathway, can protect the cells against high glucose-induced cell injury in renal tubular cells [49]. Activation of polyol pathway in response to high glucose has been reported to cause a sevenfold increase in sorbitol production in renal proximal tubules [50]. Our results reveal that aldose reductase expression was increased by about 1.5-fold with high glucose treatment as compared to control at 48 hours. Similar inductions of AR protein expression have been reported in studies using mesangial cells cultured under high glucose conditions [29, 48].

Coincubation of NRK-52E cells with 1 μM epalrestat (dose based on the literature [34] and our pilot studies) has prevented mitochondrial depolarization and loss of cell
viability induced by high glucose. These findings suggest that AR inhibition can protect renal cells against high glucose-induced mitochondrial alterations and improve cell survival. In addition, cell cycle analysis was performed to determine the effects of high glucose on cell cycle progression. Our results showed that incubation with high glucose for 48 h increased the proportion of cells in G1 phase as compared to control (59% versus 51%, resp.). Consistent with our findings, a similar G1 phase arrest has been observed in other studies using different types of renal tubular cells [8]. Together, these findings suggest that tubular renal cell hypertrophy occurs in cell cycle-dependent manner [8, 32, 51].

Although treatment with epalrestat did not block the effects of high glucose on cell cycle in our model, it ameliorated high glucose-mediated acute activation of Akt and ERK pathways. As mentioned earlier, both pathways are actively involved in DN and contribute to development of many of its pathologic features. Therefore, our results suggest that AR inhibition exerts a protective effect on kidney cells through attenuation of Akt and ERK dependent pathways. This finding is in line with another study, which showed that transfecting mesangial cells with AR gene augmented high glucose-mediated activation of Akt and ERK pathways in these cells [29].

In support to our findings, inhibiting aldose reductase has been shown to reverse high glucose-induced production of ECM proteins such as fibronectin [29]. Nevertheless, specific inhibition of aldose reductase with enzyme inhibitors is extremely challenging due to its extensive homology with other aldo-keto reductase family members and makes it hard to find specific inhibitors that are devoid of properties to block other aldo-keto enzymes involved in protective physiological detoxification of toxic aldehydes formed within cells.

5. Conclusions

In summary, in vitro exposure to high glucose acutely activates Akt and ERK pathways and induces pathologic changes such as decreases in cell viability and depolarization of mitochondrial membrane potential in renal tubular cells (Figure 8). These pathologic alterations in signaling pathways and cellular organelles initiated by hyperglycemia could potentially contribute to high glucose-induced renal injury. Most importantly, our studies demonstrate that polyol pathway plays a crucial role in development of renal tubular cell injury in a high glucose milieu, and inhibiting its rate-limiting enzyme aldose reductase (AR) protects renal cells against high glucose-mediated deleterious effects (Figure 8). Further studies in vitro and in vivo are required to ascertain their therapeutic potential of AR inhibitors to prevent and/or treat DN.

Abbreviations

4E-BP1: Eukaryotic translation initiation factor
AGC: Advanced glycation end products
AR: Aldose reductase

Disclosure

The sponsor had no involvement in the study design, data collection, analysis and interpretation of data, writing the manuscript, or in the decision to submit the article for publication.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.
Acknowledgments

This manuscript is based on the thesis of Heba El Gamal, and this study was funded by Intramural Student Research Grants awarded by the Office of Academic Research, Qatar University (nos. QUST-CPH-SPR-12/13-4, QUST-CPH-FALL-13/14-5, QUST-CPH-SPR-13/14-7, QUST-CPH-FALL-14/15-6, and QUST-CPH-SPR-14/15-15).

References

[1] Statistics about Diabetes: American Diabetes Association 2014, http://www.diabetes.org/diabetes-basics/statistics/.

[2] B. Vujčić, S. Rački, T. Türk, Z. Crnčević-Orlić, and G. Đorđević, “Diabetic nephropathy,” in Pathophysiology and Complications of Diabetes Mellitus, chapter 4, 2012.

[3] A. O. Phillips and R. Steadman, “Diabetic nephropathy: the central role of renal proximal tubular cells in tubulointerstitial injury,” Histology and Histopathology, vol. 17, no. 1, pp. 247–252, 2002.

[4] W.-J. Ni, L.-Q. Tang, and W. Wei, “Research progress in signal pathway in diabetic nephropathy,” Diabetes/Metabolism Research and Reviews, vol. 31, no. 3, pp. 221–233, 2015.

[5] M. Osaki, M. Oshimura, and H. Ito, “PI3K-Akt pathway: its functions and alterations in human cancer,” Apoptosis, vol. 9, no. 6, pp. 667–676, 2004.

[6] J. C. Krepinsky, Y. Li, Y. Chang et al., “Akt mediates mechanical strain-induced collagen production by mesangial cells,” Journal of the American Society of Nephrology, vol. 16, no. 6, pp. 1661–1672, 2005.

[7] X. Li, U. Talts, J. F. Talts, E. Arman, P. Ekblom, and P. Lonai, “Akt/PKB regulates laminin and collagen IV isotypes of the basement membrane,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 25, pp. 14416–14421, 2001.

[8] L. Sun, V. K. Kondeti, P. Xie, K. Raparia, and Y. S. Kanwar, “Epac-mediated, high glucose-induced renal proximal tubular cells hypertrophy via the Akt/p21 pathway,” The American Journal of Pathology, vol. 179, no. 4, pp. 1706–1718, 2011.

[9] T.-D. Chuang, J.-Y. Guh, S.-J. Chiou et al., “Phosphoinositide 3-kinase is required for high glucose-induced hypertrophy and p21WAF1 expression in LLC-PK1 cells,” Kidney International, vol. 71, no. 9, pp. 867–874, 2007.

[10] D. Senthil, G. G. Choudhury, C. McLaurin, and B. S. Kasinath, “Vascular endothelial growth factor induces protein synthesis in renal epithelial cells: a potential role in diabetic nephropathy,” Kidney International, vol. 64, no. 2, pp. 468–479, 2003.

[11] R. Roskoski Jr., “ERK1/2 MAP kinases: structure, function, and regulation,” Pharmacological Research, vol. 66, no. 2, pp. 105–143, 2012.

[12] D. A. Long, K. L. Price, J. Herrera-Acosta, and R. J. Johnson, “How does angiotensin II cause renal injury?” Hypertension, vol. 43, no. 4, pp. 722–723, 2004.

[13] S. Hoshi, K.-I. Nomoto, J. Kuromitsu, S. Tomari, and M. Nagata, “High glucose induced VEGF expression via PKC and ERK in glomerular podocytes,” Biochemical and Biophysical Research Communications, vol. 290, no. 1, pp. 177–184, 2002.

[14] M. Toyoda, D. Suzuki, M. Honma et al., “High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy,” Kidney International, vol. 66, no. 3, pp. 1107–1114, 2004.

[15] C. Zhu, “Aldose reductase inhibitors as potential therapeutic drugs of diabetic complications,” in Diabetes Mellitus—Insights and Perspectives, O. O. Oguntibeju, Ed., chapter 2, InTech, Rijeka, Croatia, 2013.

[16] O. A. Barski, S. M. Tipparaju, and A. Bhatnagar, “The aldoketo reductase superfamily and its role in drug metabolism and detoxification,” Drug Metabolism Reviews, vol. 40, no. 4, pp. 553–624, 2008.

[17] W. H. Tang, K. A. Martin, and J. Hwa, “Aldose reductase, oxidative stress, and diabetic mellitus,” Frontiers in Pharmacology, vol. 3, article 87, 2012.

[18] A. Beyer-Mears, E. Cruz, T. Edelist, and E. Varagiannis, “Diminished proteinuria in diabetes mellitus by sorbinil, and aldose reductase inhibitor,” Pharmacology, vol. 32, no. 1, pp. 52–60, 1986.

[19] N. Passariello, J. Sepe, G. Marrazzo et al., “Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy,” Diabetes Care, vol. 16, no. 5, pp. 789–795, 1993.

[20] K. Iso, H. Tada, K. Kuboki, and T. Inokuchi, “Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients,” Journal of Diabetes and Its Complications, vol. 15, no. 5, pp. 241–244, 2001.

[21] R. G. Tilton, K. Chang, G. Pugliese et al., “Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors,” Diabetes, vol. 38, no. 10, pp. 1258–1270, 1989.

[22] M. L. McCaleb, J. Sredy, J. Millen, D. M. Ackerman, and D. Dvornik, “Prevention of urinary albumin excretion in 6 month streptozocin-diabetic rats with the aldose reductase inhibitor tolrestat,” Journal of Diabetic Complications, vol. 2, no. 1, pp. 16–18, 1988.

[23] M. M. Pedersen, J. S. Christiansen, and C. E. Mogensen, “Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 mo of aldose reductase inhibition,” Diabetes, vol. 40, no. 5, pp. 527–531, 1991.

[24] N. Bank, P. Mower, H. S. Aynedjian, B. M. Wilkes, and S. Silverman, “Sorbinil prevents glomerular hyperperfusion in diabetic rats,” American Journal of Physiology, vol. 256, pp. F1000–F1006, 1989.

[25] P. J. Oates, “Aldose reductase inhibitors and diabetic kidney disease,” Current Opinion in Investigational Drugs, vol. 11, no. 4, pp. 402–416, 2010.

[26] H. Ishii, H. Tada, and S. Isogai, “An aldose reductase inhibitor prevents glucose-induced increase in transforming growth factor-β and protein kinase C activity in cultured human mesangial cells,” Diabetologia, vol. 41, no. 3, pp. 362–364, 1998.

[27] R. J. Keogh, M. E. Dunlop, and R. G. Larkins, “Effect of inhibition of aldose reductase on glucose flux, diacylglycerol formation, protein kinase C, and phospholipase A2 activation,” Metabolism: Clinical and Experimental, vol. 46, no. 1, pp. 41–47, 1997.

[28] A. O. Phillips, R. Steadman, K. Morrissey, J. Martin, L. Eynstone, and J. D. Williams, “Exposure of human renal proximal tubular cells to glucose leads to accumulation of type IV collagen and fibronectin by decreased degradation,” Kidney International, vol. 52, no. 4, pp. 973–984, 1997.

[29] P. Huang, Y. Zhang, T. Jiang, W. Zeng, and N. Zhang, “Role of aldose reductase in the high glucose induced expression of fibronectin in human mesangial cells,” Molecular Biology Reports, vol. 37, no. 6, pp. 3017–3021, 2010.
J.-S. Huang, L.-Y. Chuang, J.-Y. Guh, Y.-J. Huang, and M. D. Feliers, S. D. Duraisamy, J. L. Faulkner et al., “Activation of renal proximal tubular cells,” *Free Radical Biology and Medicine*, vol. 46, no. 8, pp. 1149–1157, 2009.

S.-H. Park, H.-J. Choi, J.-H. Lee, C.-H. Woo, J.-H. Kim, and H.-J. Han, “High glucose inhibits renal proximal tubule cell proliferation and involves PKC, oxidative stress, and TGF-β1,” *Kidney International*, vol. 59, no. 5, pp. 1695–1705, 2001.

L. Sun, L. Xiao, J. Nie et al., “p66Shc mediates high-glucose and angiotensin II-induced oxidative stress renal tubular injury via mitochondrial-dependent apoptotic pathway,” *American Journal of Physiology—Renal Physiology*, vol. 299, no. 5, pp. F1014–F1025, 2010.

L. Xiao, X. Zhu, S. Yang et al., “Rap1 ameliorates renal tubular injury in diabetic nephropathy,” *Diabetes*, vol. 63, no. 4, pp. 1366–1380, 2014.

L. Sun, P. Xie, J. Wada et al., “Rap1B GTPase ameliorates glucose-induced mitochondrial dysfunction,” *Journal of the American Society of Nephrology*, vol. 19, no. 12, pp. 2293–2301, 2008.

J. Zdychová and R. Komers, “Emerging role of Akt kinase/protein kinase B signaling in pathophysiology of diabetes and its complications,” *Physiological Research*, vol. 54, no. 1, pp. 1–16, 2005.

D. Wu, F. Peng, B. Zhang, A. J. Ingram, B. Gao, and J. C. Krepsinsky, “Collagen I induction by high glucose levels is mediated by epidermal growth factor receptor and phosphoinositide 3-kinase/Akt signalling in mesangial cells,” *Diabetologia*, vol. 50, no. 9, pp. 2008–2018, 2007.

D. Wu, F. Peng, B. Zhang et al., “PKC-β1 mediates glucose-induced akt activation and TGF-β1 upregulation in mesangial cells,” *Journal of the American Society of Nephrology*, vol. 20, no. 3, pp. 554–566, 2009.

N. Blaes, C. Pecher, M. Mehrenberger et al., “Bradykinin inhibits high glucose- and growth factor-induced collagen synthesis in mesangial cells through the B2-kinin receptor,” *American Journal of Physiology—Renal Physiology*, vol. 303, no. 2, pp. F293–F303, 2012.

D. Feliers, S. Duraisamy, J. L. Faulkner et al., “Activation of renal signaling pathways in db/db mice with type 2 diabetes,” *Kidney International*, vol. 60, no. 2, pp. 495–504, 2001.

M. Haneda, S.-I. Araki, M. Togawa, T. Sugimoto, M. Isono, and R. Kikkawa, “Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions,” *Diabetes*, vol. 46, no. 5, pp. 847–853, 1997.

M. Isono, M. C. Iglesias-De La Cruz, S. Chen, S. W. Hong, and F. N. Ziyadeh, “Extracellular signal-regulated kinase mediates stimulation of TGF-β1 and matrix by high glucose in mesangial cells,” *Journal of the American Society of Nephrology*, vol. 11, no. 12, pp. 2222–2230, 2000.

H. Hua, H. J. Goldberg, I. G. Fantus, and C. I. Whiteside, “High glucose—enhanced mesangial cell extracellular signal—regulated protein kinase activation and α1(IV) collagen expression in response to endothelin-1: role of specific protein kinase C isozymes,” *Diabetes*, vol. 50, no. 10, pp. 2376–2383, 2001.

J.-S. Huang, L.-Y. Chuang, J.-Y. Guh, Y.-J. Huang, and M.-S. Hsu, “Antioxidants attenuate high glucose–induced hypertrophic growth in renal tubular epithelial cells,” *American Journal of Physiology - Renal Physiology*, vol. 293, no. 4, pp. F1072–F1082, 2007.

H. Fujita, S. Omori, K. Ishikura, M. Hida, and M. AwaZu, “ERK and p38 mediate high-glucose-induced hypertrophy and TGF-β expression in renal tubular cells,” *American Journal of Physiology—Renal Physiology*, vol. 286, no. 1, pp. F120–F126, 2004.

N. S. Nahman Jr., K. L. Leonhart, F. G. Cosio, and C. L. Hebert, “Effects of high glucose on cellular proliferation and fibronectin production by cultured human mesangial cells,” *Kidney International*, vol. 41, no. 2, pp. 396–402, 1992.

M. T. Lindenmeyer, M. P. Rastaldi, M. Ikeda et al., “Proteinuria and hyperglycemia induce endoplasmic reticulum stress,” *Journal of the American Society of Nephrology*, vol. 19, no. 11, pp. 2225–2236, 2008.

W. Liu, P. Liu, S. Tao et al., “Berberine inhibits aldose reductase and oxidative stress in rat mesangial cells cultured under high glucose,” *Archives of Biochemistry and Biophysics*, vol. 475, no. 2, pp. 128–134, 2008.

H. El Gamal, “Standardization of an in vitro model of diabetic nephropathy in renal tubular cells and investigation of the role of aldose reductase pathway in high-glucose-induced renal cell injury [M.S. thesis], Qatar University, 2015.

A. J. Bleyer, P. Fumo, E. R. Snipes, S. Goldfarb, D. A. Simmons, and F. N. Ziyadeh, “Polyol pathway mediates high glucose-induced collagen synthesis in proximal tubule,” *Kidney International*, vol. 45, no. 3, pp. 659–666, 1994.

M.-L. Yang, J.-Y. Guh, Y.-L. Yang, C.-C. Chang, and L.-Y. Chuang, “Captopril reverses high glucose-induced effects on LLC-PKI cells partly by enhancing facilitative glucose transporter messenger RNA expressions,” *Biochemistry and Molecular Biology International*, vol. 41, no. 3, pp. 511–519, 1997.